Atea Pharmaceuticals, Inc. (AVIR)
4.115
-0.20
(-4.52%)
USD |
NASDAQ |
Oct 30, 16:00
4.115
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Enterprise Value : 126.64M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 126.64M |
| October 28, 2026 | 123.43M |
| October 27, 2026 | 115.41M |
| October 26, 2026 | 114.61M |
| October 23, 2026 | 104.99M |
| October 22, 2026 | 105.79M |
| October 21, 2026 | 108.19M |
| October 20, 2026 | 139.07M |
| October 19, 2026 | 133.06M |
| October 16, 2026 | 127.44M |
| October 15, 2026 | 144.29M |
| October 14, 2026 | 152.31M |
| October 13, 2026 | 180.38M |
| October 12, 2026 | 184.39M |
| October 09, 2026 | 194.01M |
| October 08, 2026 | 194.41M |
| October 07, 2026 | 182.78M |
| October 06, 2026 | 187.60M |
| October 05, 2026 | 192.41M |
| October 02, 2026 | 192.41M |
| October 01, 2026 | 190.00M |
| September 30, 2026 | 198.83M |
| September 29, 2026 | 196.42M |
| September 28, 2026 | 198.02M |
| September 25, 2026 | 195.62M |
| Date | Value |
|---|---|
| September 24, 2026 | 195.62M |
| September 23, 2026 | 204.44M |
| September 22, 2026 | 233.31M |
| September 21, 2026 | 216.47M |
| September 18, 2026 | 208.45M |
| September 17, 2026 | 202.84M |
| September 16, 2026 | 194.01M |
| September 15, 2026 | 200.43M |
| September 14, 2026 | 207.65M |
| September 11, 2026 | 206.85M |
| September 10, 2026 | 196.42M |
| September 09, 2026 | 203.64M |
| September 08, 2026 | 236.52M |
| September 04, 2026 | 248.55M |
| September 03, 2026 | 247.75M |
| September 02, 2026 | 238.13M |
| September 01, 2026 | 221.28M |
| August 31, 2026 | 210.05M |
| August 28, 2026 | 210.86M |
| August 27, 2026 | 218.07M |
| August 26, 2026 | 222.89M |
| August 25, 2026 | 216.47M |
| August 24, 2026 | 222.89M |
| August 21, 2026 | 216.47M |
| August 20, 2026 | 210.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -50.89M |
| CorMedix, Inc. | 481.18M |
| Eloxx Pharmaceuticals, Inc. | -8.686M |
| Breakthrough Chemistry, Inc. | 0.2216M |
| BioStem Technologies, Inc. | 17.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.93M |
| Total Expenses (Quarterly) | 32.93M |
| EPS Diluted (Quarterly) | -0.4114 |
| Earnings Yield | -50.82% |
| Normalized Earnings Yield | -50.82 |